Biotech group CSL has bought a blood collection company to fix its supply problems in China, as part of its ambition to be the country’s biggest plasma collector.
The Australian company gathers plasma from US donors, and exports a protein found within it to China, where a spate of liver diseases has left local companies unable to keep up with demand.
But restrictions on the kinds of plasma proteins that can be exported to China have prompted CSL, one of Australia’s largest companies with a $47.5bn market capitalisation, to buy a Chinese company, giving it the capacity to collect plasma in China.
您已閱讀23%（600字），剩余77%（1990字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。